BRA
ABBV icon

Bender Robert & Associates’s AbbVie ABBV Stock Holding History

Bender Robert & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$520K Sell
2,393
-365
-13% -$81K 0.12% 31
2025
Q4 		$630K Sell
2,758
-224
-8% -$51K 0.13% 29
2025
Q3 		$690K Sell
2,982
-350
-11% -$71.3K 0.15% 29
2025
Q2 		$618K Sell
3,332
-32
-1% -$5.95K 0.14% 28
2025
Q1 		$705K Sell
3,364
-933
-22% -$181K 0.18% 27
2024
Q4 		$764K Sell
4,297
-32
-0.7% -$5.88K 0.18% 29
2024
Q3 		$855K Buy
+4,329
New +$808K 0.18% 29
2024
Q2 		– Sell
-8,524
Closed -$1.41M – 43
2024
Q1 		$1.55M Sell
8,524
-633
-7% -$109K 0.36% 26
2023
Q4 		$1.42M Sell
9,157
-3,727
-29% -$543K 0.36% 28
2023
Q3 		$1.92M Sell
12,884
-731
-5% -$107K 0.56% 26
2023
Q2 		$1.83M Sell
13,615
-17,349
-56% -$2.54M 0.51% 26
2023
Q1 		$4.93M Sell
30,964
-151
-0.5% -$23.1K 1.53% 19
2022
Q4 		$5.03M Sell
31,115
-1,176
-4% -$180K 1.88% 16
2022
Q3 		$4.33M Sell
32,291
-80
-0.2% -$11.5K 1.68% 17
2022
Q2 		$4.96M Sell
32,371
-799
-2% -$122K 1.9% 15
2022
Q1 		$5.38M Sell
33,170
-1,010
-3% -$147K 1.53% 16
2021
Q4 		$3.69M Hold
34,180
– – 1.06% 21
2021
Q3 		$3.69M Sell
34,180
-332
-1% -$37.9K 1.06% 21
2021
Q2 		$3.89M Sell
34,512
-150
-0.4% -$16.9K 1.1% 22
2021
Q1 		$3.75M Sell
34,662
-5
-0% -$535 1.21% 20
2020
Q4 		$3.71M Buy
34,667
+1,265
+4% +$122K 1.18% 21
2020
Q3 		$2.93M Sell
33,402
-1,905
-5% -$179K 1.05% 23
2020
Q2 		$3.47M Sell
35,307
-1,788
-5% -$157K 1.37% 19
2020
Q1 		$2.83M Sell
37,095
-1,765
-5% -$150K 1.51% 21
2019
Q4 		$3.44M Sell
38,860
-2,432
-6% -$202K 1.55% 22
2019
Q3 		$3.13M Sell
41,292
-1,764
-4% -$121K 1.56% 21
2019
Q2 		$2.92M Sell
43,056
-4,129
-9% -$325K 1.38% 24
2019
Q1 		$3.8M Sell
47,185
-8,631
-15% -$706K 1.86% 21
2018
Q4 		$5.15M Sell
55,816
-874
-2% -$76.9K 2.97% 12
2018
Q3 		$5.36M Buy
56,690
+15
+0% +$1.42K 2.44% 16
2018
Q2 		$5.25M Buy
56,675
+406
+0.7% +$39.7K 2.75% 15
2018
Q1 		$5.33M Sell
56,269
-1,754
-3% -$193K 2.96% 15
2017
Q4 		$5.61M Sell
58,023
-468
-0.8% -$44.1K 3.11% 15
2017
Q3 		$5.2M Sell
58,491
-740
-1% -$56.3K 2.99% 12
2017
Q2 		$4.29M Buy
59,231
+10
+0% +$672 2.63% 16
2017
Q1 		$3.86M Sell
59,221
-1,091
-2% -$68.6K 2.49% 19
2016
Q4 		$3.78M Sell
60,312
-1,130
-2% -$69K 2.68% 17
2016
Q3 		$3.88M Sell
61,442
-380
-0.6% -$24.6K 2.56% 18
2016
Q2 		$3.83M Buy
61,822
+367
+0.6% +$22.4K 2.7% 15
2016
Q1 		$3.51M Sell
61,455
-2,883
-4% -$161K 2.38% 16
2015
Q4 		$3.81M Sell
64,338
-1,221
-2% -$70.3K 2.44% 15
2015
Q3 		$3.57M Sell
65,559
-1,251
-2% -$81.4K 2.41% 18
2015
Q2 		$4.49M Buy
+66,810
New +$4.36M 2.66% 16

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bender Robert & Associates's ABBV Position: Q1 2026 in Review

Bender Robert & Associates reduced its AbbVie (ABBV) stake by 13% in Q1 2026, selling an estimated $81K and leaving 2,393 shares worth $520K. The position accounts for 0.12% of the portfolio, ranked #31.

Bender Robert & Associates first reported a position in ABBV in Q2 2015 and has held it in 43 quarters since. The position peaked at $5.61M in Q4 2017. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Bender Robert & Associates held 2,393 shares of AbbVie worth $520K as of Q1 2026.
  • Bender Robert & Associates sold 365 AbbVie shares in Q1 2026, an estimated $81K.
  • AbbVie made up 0.12% of Bender Robert & Associates's portfolio in Q1 2026, its #31 holding.
  • Bender Robert & Associates first reported a position in AbbVie in Q2 2015 and has held it in 43 quarters since.
  • Bender Robert & Associates's AbbVie position peaked at $5.61M in Q4 2017.
  • 4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Bender Robert & Associates's 13F filing for Q1 2026, filed 23 Apr 2026.